COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Ketogenic Diets for Symptoms of Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01364545
Recruitment Status : Unknown
Verified May 2011 by University of Oxford.
Recruitment status was:  Recruiting
First Posted : June 2, 2011
Last Update Posted : June 2, 2011
Information provided by:
University of Oxford

Brief Summary:

Parkinson's disease is a progressive condition that harms nerve cells of the brain (neurodegeneration). Current treatments for Parkinson's disease (including levodopa and deep brain stimulation) improve certain symptoms but are not thought to improve the underlying neurodegenerative disease process (they are not a "cure"). The cause of Parkinson's disease is unknown. However, some evidence suggests that tiny structures in the investigators cells called "mitochondria" might be involved. Mitochondria are the powerhouses that produce fuel for the investigators cells. Failure of these 'powerhouses' to supply the energy needs of certain nerve cells might lead to Parkinson's disease. Preliminary evidence suggests that a food called 'ketones' might be able to enhance the function of mitochondria and improve Parkinson's disease symptoms and possibly even the neurodegenerative process. In this study, the investigators would like to investigate this possibility by giving patients with Parkinson's disease dietary supplements of 'ketone esters' in a drink. The investigators will then assess if this improves symptoms of Parkinson's disease.

The study design is a prospective, double blinded, randomised, controlled trial.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Dietary Supplement: Ketone ester drink Dietary Supplement: Placebo (carbohydrate containing) drink Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Ketogenic Diets for Symptoms of Parkinson's Disease
Study Start Date : May 2011
Estimated Primary Completion Date : May 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Ketone ester drink Vs placebo drink
Ketone ester drink Vs placebo drink (cross over study - all patients will recieve both)
Dietary Supplement: Ketone ester drink
Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)

Dietary Supplement: Placebo (carbohydrate containing) drink
Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily

Primary Outcome Measures :
  1. Unified Parkinson's Disease rating Scale, part III (motor) [ Time Frame: 5 days ]
    Difference between ketone versus placebo scores

Secondary Outcome Measures :
  1. Timed motor tasks as per CAPSIT [ Time Frame: 5 days ]
    Hand/Arm movements, 7m walk, 9 hole peg test

  2. Computerised reaction time and cogntive tests [ Time Frame: 5 days ]


    • SRT and CRT (Task: MOT "Motor screening" practice then RTI "Reaction time")
    • Spatial working memory (Task: SSP "spatial span")
    • Set shifting and visual discrimination (Task: BLC "big circle little circle" practice then IED "intra-extra dimensional shift)
    • Continuous performance task (alertness) (Task: RVP - "Rapid visual processing")

  3. Unified Parkinson's disease rating scale, parts I, II, IV [ Time Frame: 5 days ]
    Difference between ketone versus placebo scores

  4. Dopaminergic medication requirements (expressed as levodopa dose equivalent, mg/day) [ Time Frame: 5 days ]
    Difference between ketone versus placebo doses

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   42 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with Primary Parkinson's disease fulfilling UK Brain Bank criteria
  • Age of onset of Parkinson's disease symptoms > 40 years old
  • Duration of symptoms over 2 years

Exclusion Criteria:

  • Dementia
  • Active psychosis
  • Deep brain stimulation or apomorphine infusion
  • Severe motor fluctuations
  • Significant metabolic or uncontrolled medical cormorbidity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01364545

Layout table for location information
United Kingdom
John Radcliffe Hospital Recruiting
Oxford, Oxfordshire, United Kingdom, OX39DU
Contact: Wesley Thevathasan, FRACP   
Principal Investigator: Wesley Thevathasan, FRACP         
Sponsors and Collaborators
University of Oxford
Layout table for additonal information
Responsible Party: Dr Wesley Thevathasan, Honorary consultant neurologist, University of Oxford and the John Radcliffe Hospital, Oxford Identifier: NCT01364545    
Other Study ID Numbers: 10/H0606/74
First Posted: June 2, 2011    Key Record Dates
Last Update Posted: June 2, 2011
Last Verified: May 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases